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Meniere disease (MD) is a heterogeneous clinical condition characterized by sensori-
neural hearing loss, episodic vestibular symptoms, and tinnitus associated with several 
comorbidities, such as migraine or autoimmune disorders (AD). The frequency of 
bilateral involvement may range from 5 to 50%, and it depends on the duration of the 
disease. We have performed a two-step cluster analysis in 398 patients with bilateral MD 
(BMD) to identify the best predictors to define clinical subgroups with a potential different 
etiology to improve the phenotyping of BMD and to develop new treatments. We have 
defined five clinical variants in BMD. Group 1 is the most frequently found, includes 46% 
of patients, and is defined by metachronic hearing loss without migraine and without 
AD. Group 2 is found in 17% of patients, and it is defined by synchronic hearing loss 
without migraine or AD. Group 3, with 13% of patients, is characterized by familial MD, 
while group 4, that includes 12% of patients, is associated by the presence of migraine 
in all cases. Group 5 is found in 11% of patients and is defined by AD. This approach 
can be helpful in selecting patients for genetic and clinical research. However, further 
studies will be required to improve the phenotyping in these clinical variants for a better 
understanding of the diverse etiological factors contributing to BMD.
Keywords: cluster analysis, vestibular disorders, hearing loss, tinnitus, Meniere’s disease, migraine, autoimmune 
disorders, inner ear
TaBle 2 | clinical phenotype in sporadic and familial Meniere disease 
with at least 5 years since the onset of the disease.
Variables FMD (n = 52) sMD (n = 258) p-value
Age, mean (SD) 55.5 (12.7) 61.5 (11.1) 0.001
Gender (% women) 34 (65.4) 147 (57.0) 0.28
Age of onset (SD) 39 (12.9) 44.8 (13.1) 0.003
Age of onset ≤40, n (%) 28 (53.8) 96 (37.2) 0.03
Time course (years), 
mean (SD)
16.3 (8.7) 16.3 (9.4) 0.96
Synchronic, n (%) 11 (21.6) 72 (27.9) 0.39
Metachronic, n (%) 40 (78.4) 186 (72.1)
Hearing loss at diagnosis, 
mean (SD)
51.9 (15.5) 56.6 (17.8) 0.092
Headache, n (%) 23 (44.2) 92 (36.1) 0.27
Migraine, n (%) 13 (25.0) 44 (17.3) 0.24
Rheumatoid history, n (%) 10 (20.4) 25 (9.8) 0.048
Hearing stage, n (%)
1 0 (0.0) 4 (1.6) 0.58
2 9 (17.6) 35 (13.6)
3 28 (54.9) 131 (51.0)
4 14 (27.5) 87 (33.9)
Cardiovascular risk
High blood pressure, n (%) 13 (26.5) 93 (39.7) 0.1
Dyslipidemia, n (%) 21 (42.0) 111 (47.6) 0.53
Type 2 diabetes, n (%) 12 (24.0) 41 (17.4) 0.32
Smoking, n (%) 15 (30) 53 (21.5) 0.2
Tumarkin crisis, n (%) 17 (35.4) 63 (25.5) 0.16
Functional Scale, n (%)
1 9 (17.6) 53 (21.3) 0.81
2 15 (29.4) 71 (28.5)
3 10 (19.6) 58 (23.3)
4 7 (13.7) 35 (14.1)
5 7 (13.7) 25 (10.0)
6 3 (5.9) 7 (2.8)
SMD, sporadic Meniere disease; FMD, familial Meniere disease.
Significant p values in bold.
TaBle 1 | list of abbreviations.
AAO-HNS American Academy Otolaryngology – Head Neck Surgery
AD Autoimmune disorders/disease
AIED Autoimmune inner ear disorder
BMD Bilateral Meniere disease
BMD type 1 Metachronic hearing loss
BMD type 2 Synchronic hearing loss
BMD type 3 Familial Meniere disease
BMD type 4 Meniere disease + migraine
BMD type 5 Meniere disease + autoimmune disease
FMD Familial Meniere disease
MD Meniere disease
MRI Magnetic resonance imaging
RCT Randomized clinical trials
SNHL Sensorineural hearing loss
SMD Sporadic Meniere disease
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inTrODUcTiOn
Meniere’s disease (MD) is a long-lasting disorder of the inner 
ear characterized by episodes of vertigo lasting from 20 min to 
hours, low-to-middle frequencies sensorineural hearing loss 
(SNHL, Table  1), tinnitus, and aural fullness (1). MD patients 
have phenotypic heterogeneity (2), and it is difficult to define the 
outcome of the disease in its early stages. Although the frequency 
of the spells of vertigo is typically greater during the earlier years 
(3–5), balance problems are observed during the course of the 
disease and might become severe if patients progress to a bilateral 
vestibular hypofunction (6, 7). Most of the patients start with 
SNHL in one ear, and it can appear in the other after several years 
(metachronic SNHL) (8), but a significant number of individuals 
show simultaneous SNHL (synchronic SNHL). Bilateral involve-
ment is a major concern for patients because of the loss of vestibu-
lar function, and bilateral SNHL has a significant influence in the 
health-related quality of life in MD patients (9).
Several studies have reported contralateral ear involvement 
between 2 and 73% of cases, depending on the interval of 
follow-up and the diagnostic criteria used. However, if bilateral 
MD (BMD) was defined as the combination of clinical symp-
toms and audiometric tests, the frequency would be 2–47% (7). 
Some studies describe an interval of 5 years where the incidence 
was 10–35% (8, 10–13), while in other studies, with a follow-
up of 10 years or more, the frequency of BMD ranges from 20 
(14–16) to 46% (17). However, more than 20 years of follow-up 
have also been described, and the incidence rate of bilaterality 
rises up to 47% (18–22). Although there is a great disparity in 
the percentage of individuals with bilateral involvement, most 
of the studies highlighted that the number of patients with 
contralateral ear involvement increased with the duration of 
the disease (18, 21, 22).
Several comorbidities have been associated with MD, including 
autoimmune disorders and migraine. So, MD has been previously 
associated with several autoimmune diseases, such as systemic 
lupus erythematous, psoriasis, or rheumatoid arthritis (6, 23), and 
autoimmunity has been suggested as a potential cause in MD (24) 
relying on the results of proteomic studies achieved in small series 
of patients (24–26). However, high levels of circulating immune 
complexes were not found in most of the patients with MD (27). 
Furthermore, autoimmune mechanisms seem to be associated 
with the pathogenesis of some types of SNHL (28, 29), such as 
sudden SNHL (30), promptly progressive bilateral SNHL (31), 
and MD (32–34). Additionally, several genes of the immune 
system have been studied in case–control studies (35–38), but 
they have not been replicated. Moreover, some data suggest that 
allelic variants of MICA and TLR10 genes, involved in the innate 
immune response, may influence the susceptibility and time 
course of hearing loss of MD in European population (39, 40).
Migraine has been consistently found to be more common in 
MD than in the general population in case–control studies (41), 
but it is not clear if this association has any role in the patho-
physiology of MD. Vestibular migraine (VM), the condition of 
episodic vestibular symptoms linked to migraine spectrum (42), 
may occur in some patients concomitantly with MD (43).
Genetic factors are probably relevant in a subset of patients 
with MD. So, familial MD was first described in 1949 by Brown 
(44), and many studies have described familial cases of MD (45). 
The genetic contribution to MD has been recently reviewed 
(46, 47), and there are several evidences to support a genetic 
origin in MD. These evidences include (a) the prevalence is 
higher in European descent population than in Asian (48) or 
African populations (49) and (b) familiar aggregation has been 
observed in 6% in South Korea and 8–9% in Spain (2), being 
TaBle 3 | autoimmune diseases and other rheumatoid conditions 
observed in patients with bilateral Meniere disease.
autoimmune diseases N
Rheumatoid arthritis 10
Fibromyalgia 6
Arthrosis 5
Ankylosing spondylitis 5
Psoriasis 4
Hypothyroidism 3
Sjogren syndrome 3
Type 1 diabetes 2
Rosacea 2
Graves–Basedow disease 2
Systemic lupus erythematous 2
Psoriatic arthritis 1
Autoimmune inner ear disease 1
Polymyalgia rheumatica 1
Inflammatory bowel disease 1
Cogan syndrome 1
Hip synovitis 1
Carpal tunnel syndrome 1
Undetermined 10
FigUre 1 | age of onset in bilateral Meniere disease. Distribution of frequencies in familial and sporadic cases shows an earlier onset in FMD.
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DTNA and FAM136A genes involved in autosomal dominant 
familial MD (50).
The aim of this study is to describe the phenotype of patients 
with BMD, including comorbidities such as autoimmune diseases 
or familial aggregation, and to perform a cluster analysis to iden-
tify clinical variants in BMD.
MaTerials anD MeThODs
subjects
A multicenter, cross-sectional retrospective study was designed, 
including patients with BMD diagnosed and tracked by the 
Meniere’s Disease Consortium. For this, the clinical records of a 
total of 405 patients diagnosed with definite BMD from 16 clini-
cal centers in Spain and Portugal were reviewed in March 2016. 
MD diagnosis was established according to the diagnostic scale 
of the American Academy of Otolaryngology Head and Neck 
Surgery (AAO-HNS) (51). Familial MD (FMD) was defined if 
at least another relative (first or second degree) fulfilled all the 
criteria of definite or probable MD, according to the criteria 
established by the Barany Society International Classification for 
Vestibular Disorders (1). Patients with unilateral MD or bilateral 
BMD with less than 5  years of evolution were excluded of the 
study. Seven patients were excluded because of inconsistent data. 
This study was approved by the Institutional Review Board for 
Clinical Research (PI-13-1242).
Every patient underwent a complete neuro-otological evalua-
tion, including a pure-tone audiometry, an otoscopy, nystagmus 
examination, and a caloric testing. A brain MRI was performed 
to exclude any other possible cause of neurological symptoms. 
Patients with simultaneous SNHL in both ears were considered 
to have synchronic SNHL, while metachronic SNHL was consid-
ered if an interval longer than 1 month between the first and the 
second ear was observed.
TaBle 4 | clinical features of sporadic and familial bilateral Meniere disease stratified by the presence of autoimmune disease (aD).
Variables sporadic MD Familial MD
aD+ (n = 25) aD− (n = 230) p-value aD+ (n = 10) aD− (n = 39) p-value
Age, mean (SD) 61.7 (9.1) 61.6 (11.2) 0.94 56.5 (13.8) 55 (12.4) 0.74
Gender (% women) 18 (72.0) 128 (55.7) 0.14 6 (60.0) 26 (66.7) 0.72
Age of onset (SD) 43.4 (11.0) 45.2 (13.2) 0.5 35.9 (12.3) 40.5 (13.0) 0.31
Age of onset ≤40, n (%) 11 (44.0) 82 (35.7) 0.51 6 (60.0) 19 (48.7) 0.73
Time course (years), mean (SD) 17.4 (8.7) 16.1 (9.6) 0.52 20.7 (8.9) 14 (7.0) 0.01
Hearing loss at diagnosis, mean (SD) 57.5 (18.3) 56.7 (17.8) 0.83 52.3 (15.2) 52 (15.9) 0.96
Headache, n (%) 15 (62.5) 77 (33.5) 0.007 8 (80.0) 14 (35.9) 0.03
Migraine, n (%) 8 (33.3) 36 (15.7) 0.044 5 (50.0) 7 (17.9) 0.05
Hearing stage, n (%)
1 0 (0.0) 4 (1.7) 0.37 0 (0.0) 0 (0.0) 0.32
2 5 (20.0) 30 (13.1) 1 (11.1) 8 (20.5)
3 9 (36.0) 119 (52.0) 4 (44.4) 23 (59.0)
4 11 (44.0) 76 (33.2) 4 (44.4) 8 (20.5)
Cardiovascular risk factors
High blood pressure, n (%) 13 (59.1) 80 (37.7) 0.07 2 (20.0) 10 (27.0) 1
Dyslipidemia, n (%) 12 (50.0) 97 (46.9) 0.83 4 (40.0) 16 (42.1) 1
Type 2 diabetes, n (%) 8 (33.3) 33 (15.8) 0.046 5 (50.0) 7 (18.4) 0.09
Smoking, n (%) 6 (28.6) 47 (21.0) 0.41 3 (30.0) 12 (30.8) 1
Tumarkin crisis, n (%) 6 (27.3) 57 (25.3) 0.8 5 (50.0) 12 (32.4) 0.46
Functional Scale, n (%)
1 4 (17.4) 48 (21.3) 0.94 2 (20.0) 7 (17.9) 0.007
2 7 (30.4) 64 (28.4) 4 (40.0) 11 (28.2)
3 6 (26.1) 52 (23.1) 1 (10.0) 8 (20.5)
4 2 (8.7) 33 (14.7) 0 (0.0) 6 (15.4)
5 3 (13.0) 22 (9.8) 0 (0.0) 7 (17.9)
6 1 (4.3) 6 (2.7) 3 (30.0) 0 (0.0)
Significant p values in bold.
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Clinical variables studied were as follows: gender, duration 
of disease, age of onset, family history of MD, hearing loss at 
diagnosis, hearing stage defined as four-tone average of 0.5, 
1, 2, and 3 kHz according to the AAO-HNS criteria (stage 1, 
≤25  dB; stage 2, 26–40  dB; stage 3, 41–70  dB, and stage 4, 
>70 dB), type of headache (migraine, tension-type headache), 
history of autoimmune disease (AD), cardiovascular risk fac-
tors (high blood pressure, type 2 diabetes, dyslipidemia, and 
smoking), Tumarkin crisis, and the Functional Scale of the 
AAO-HNS.
statistical analysis
A descriptive statistical analysis was carried out using SPSS soft-
ware v.22 (SPSS Inc., Chicago, IL, USA). Data are shown as means 
with their SDs. Quantitative variables were compared using 
Student’s unpaired T-test. Qualitative variables were compared 
using crosstabs and Fisher’s exact test. Nominal p-values <0.05 
were considered statistically significant.
We carried out a two-step cluster analysis using log-likelihood 
distance measures, which can detect relationships within a 
complex dataset between patients with multiple distinct charac-
teristics. It tries to identify homogenous groups of cases based on 
the distribution of some variables (input variables). The method 
identifies the groups by running pre-clustering first and then by 
using hierarchical methods to classify and to find the optimal 
number of clusters.
Initially, we selected variables showing differences between the 
clinical groups during the descriptive analysis to test its relevance 
as predictors of clusters. The procedure was iterated several times 
until we found the minimum number of homogenous clusters. 
The final cluster analysis was applied using the four following 
categorical variables: history of autoimmune disease, onset of 
hearing loss (synchronic/metachronic), FMD or sporadic cases, 
and migraine. The four variables included produced a silhouette 
of cohesion and division of 0.8, indicative of good data partition-
ing. Two additional variables were added to the model: age of 
onset <40 years old and gender, although their contribution to 
refine the clustering was limited.
resUlTs
Three hundred ninety-eight patients with BMD were included in 
the study. There were 258 sporadic cases and 52 individuals with 
FMD (20%). Although apparently there were no clinical differ-
ences in the phenotype between sporadic and familial cases, FMD 
had an earlier age of onset (p = 0.003) and a higher prevalence 
of autoimmune comorbidities (Table  2). So, the distribution 
of frequencies for the age of onset showed that the number of 
patients starting before 40 years old was significantly higher in 
the FMD (Figure  1). Table  3 lists the autoimmune comorbid 
conditions found, being rheumatoid arthritis the most common 
in our cohort.
The clinical features in patients with sporadic and FMD were 
stratified according to the presence or absence of autoimmune 
comorbidities. In the sporadic cases, headache and migraine 
were most commonly observed in patients with autoimmune 
background (62.5 and 33%, respectively) compared with patients 
without autoimmune comorbidities (33 and 16%), suggesting 
TaBle 5 | clinical features in bilateral Meniere disease according to the 
onset of hearing loss.
Variables synchronic  
(n = 103)
Metachronic 
(n = 291)
p-value
Age, mean (SD) 61 (11.0) 60.1 (11.9) 0.49
Gender (% women) 63 (61.2) 161 (55.3) 0.36
Age of onset (SD) 46.1 (12.8) 43.5 (13.2) 0.07
Age of onset ≤40, n (%) 39 (37.9) 118 (40.5) 0.73
Time course (years), mean (SD) 14.4 (8.9) 16.2 (8.9) 0.08
Family history, n (%) 39 (39.8) 119 (43.0) 0.64
FMD, n (%) 11 (13.3) 40 (17.7) 0.39
Hearing loss at diagnosis,  
mean (SD)
55.1 (17.0) 55.9 (17.0) 0.71
Headache, n (%) 55 (53.4) 96 (33.3) 0.0004
Migraine, n (%) 25 (24.3) 49 (17.0) 0.11
Rheumatoid history, n (%) 15 (15.0) 35 (12.2) 0.49
Hearing stage, n (%)
1 1 (1.0) 6 (2.1) 0.004
2 27 (26.5) 34 (11.7)
3 42 (41.2) 152 (52.4)
4 32 (31.4) 98 (33.8)
Cardiovascular risk
High blood pressure, n (%) 47 (51.1) 109 (39.9) 0.068
Dyslipidemia, n (%) 53 (55.2) 121 (45.1) 0.097
Type 2 diabetes, n (%) 13 (13.5) 50 (18.5) 0.35
Smoking, n (%) 22 (21.8) 68 (24.5) 0.68
Tumarkin crisis, n (%) 24 (25.8) 69 (24.9) 0.89
Functional Scale, n (%)
1 14 (14.0) 73 (26.0) 0.11
2 29 (29.0) 77 (27.4)
3 26 (26.0) 55 (19.6)
4 12 (12.0) 40 (14.2)
5 16 (16.0) 27 (9.6)
6 3 (3.0) 9 (3.2)
Significant p values in bold.
FigUre 2 | age of onset in bilateral Meniere disease according to the type of hearing loss observed.
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a potential association between migraine and autoimmunity in 
patients with sporadic BMD (Table 4).
We also compared patients according to the onset of 
hearing loss (Table  5). One hundred three (26%) individuals 
developed simultaneous hearing loss in both ears (synchronic 
hearing loss, either symmetric or asymmetric), while 291 (73%) 
patients started with hearing loss in one ear and developed 
the hearing loss in the contralateral ear (metachronic hearing 
loss). Figure  2 compares the distribution of frequencies for 
the age of onset in patients with synchronic or metachronic 
hearing loss. There were no clinical differences between them, 
but the occurrence of headache was most commonly observed 
in synchronic hearing loss (p = 0.0004), and the worst hearing 
stage was observed in patients with metachronic hearing loss 
(p =  0.004).
We performed cluster analysis to identify groups of patients 
with common clinical features in BMD. Figure 3 shows the size 
of the clusters, the relevance of predictors, and the contribution of 
each predictor to define the cluster. The best predictors for clus-
tering were autoimmune history, FMD, migraine, and the onset 
of hearing loss (synchronic/metachronic). Ninety-five patients 
remained unclassified because of incomplete clinical data.
We have defined five clusters for BMD and ranked them 
according to its relative frequency (Figure  4). Cluster 1 is the 
most common, including 46.5% of patients, and it is defined 
by metachronic hearing loss without migraine, sporadic BMD, 
and no autoimmune history. Cluster 2 (17.5%) includes patients 
with synchronic hearing loss, sporadic BMD, no migraine, and 
no autoimmune history. Cluster 3 (12.9%) includes patients with 
FMD without migraine in 82% of patients. Cluster 4 (11.9%) 
consists of patients with migraine and sporadic BMD. Cluster 
5 (11.2%) groups all patients with autoimmune comorbidities, 
being 71% sporadic and 29% FMD.
Table  6 shows the five groups found and the major clinical 
differences among the groups. Comparing the age of onset by 
groups, we observe that groups 3–5 have earlier onsets than 
groups 1 and 2 (p =  0.0003). The type of hearing loss, FMD, 
migraine, and autoimmune comorbidities strongly differ among 
groups, and these variables are the basis to assign a given patient 
to each cluster.
DiscUssiOn
The diagnostic criteria for MD formulated by the Classification 
Committee of the Bárány Society state that bilateral involve-
ment is determined by hearing loss defined in the audiogram 
FigUre 3 | summary of cluster analysis in bilateral Meniere disease (BMD). (a) Pie chart showing five groups or clinical variants in BMD. (B) Bar chart ranking 
the importance of predictors to define the groups. (c) Classification of BMD in five clinical variants according to its observed frequency and lead predictor: type 1, 
metachronic sensorineural hearing loss (SNHL); type 2, synchronic SNHL; type 3, familial Meniere disease (FMD); type 4, migraine; type 5, autoimmune disease.
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(1). So, if the absolute thresholds for bone-conducted sound are 
≥35 dB HL at each of two contiguous frequencies below 2000 Hz 
in both ears, and the patient has experienced ≥2 episodes of 
spontaneous vertigo each lasting 20 min to 12 h associated with 
fluctuating aural symptoms, the diagnosis of definite BMD is 
established. The notes added to the definition also describe a 
second clinical variant when the patient develops simultane-
ous bilateral SNHL (symmetric or asymmetric) (1, 52), but no 
further clinical information was included in the definition.
Our study demonstrates that BMD is a heterogeneous disorder, 
and two-step cluster analysis is a very useful tool to define groups 
of patients with BMD according to four clinical predictors: FMD, 
autoimmune history, migraine, and the type of onset for hear-
ing loss. We selected this method since it allows the inclusion of 
quantitative and categorical variables to define clusters (53).
We present a new classification for BMD in five groups of 
patients with potential etiological implications, which probably 
will improve the diagnostic workflow and the management of 
patients with BMD. Previous studies in patients with BMD were 
focused in the diagnosis by electrocochleography or MRI (54–56), 
but they did not consider the comorbidities commonly observed, 
such as migraine or AD in some cases. The phenotype of a patient 
with an episodic vestibular syndrome should not be limited to the 
description of the inner ear symptoms, skipping crucial informa-
tion such as the familiar history of MD or migraine. Furthermore, 
the comorbidities of migraine or AD may explain the perception 
of MD as a continuum, which overlaps with migraine (57) or 
autoimmune inner ear disease (1, 58, 59).
The most remarkable finding in our study is that the five 
groups of patients identified do not overlap themselves, and each 
of them has a set of features able to define the group.
Bilateral MD type 1 is the most common clinical variant, and 
it includes patients with MD in one ear (unilateral MD), and 
FigUre 4 | schematic diagram of the five subgroups in BMD. Circle 
areas are proportional to the frequency observed in each group.
7Frejo et al. Bilateral Meniere Disease
Frontiers in Neurology | www.frontiersin.org October 2016 | Volume 7 | Article 182
they develop the hearing loss in the contralateral ear (conversion 
from unilateral to BMD). The mean age of onset was 46  years 
old, comparable to BMD type 2, but it is significantly higher than 
it was observed in the rest of the groups (types 3, 4, or 5). BMD 
type 1 has no familial or autoimmune history, and patients do not 
have migraine, so further studies are required to investigate other 
concurrent comorbidities to determine contributing factors.
Bilateral MD type 2 is the second most frequently observed 
clinical variant, and fluctuating bilateral SNHL loss may resemble 
AIED, since simultaneous SNHL with vestibular symptoms can 
occur in 50% patients with AIED (58). However, these patients 
do not have any autoimmune comorbid conditions, migraine, or 
familial history of MD. Interestingly, BMD type 2 patients show a 
vascular risk profile, since 50% of them show high blood pressure, 
and 53% have dyslipidemia. When we compared these frequen-
cies with BMD type 1, which do not differ in age or sex profile to 
BMD type 2, they were not significantly different (p = 0.078), but 
further studies should assess the role of vascular risk factors in 
labyrinthine microcirculation in MD.
Comparing the hearing stage for the worst ear, it seems to 
be worse in BMD type 1 (metachronic SNHL) than in type 2 
(synchronic SNLH). Since both groups do not differ for the age 
of onset, duration of disease, or gender distribution, we cannot 
determine the reason for the severe SNHL in the first ear in BMD 
type 1.
Bilateral MD type 3 includes all patients with familiar his-
tory of MD, and we could subtype them in two subgroups (3a 
with migraine, 82%, and 3b BMD without migraine 18%). 
These findings confirm the early description of families with 
MD co-segregating migraine and MD (60) and the more recent 
description of FMD without migraine (2, 61, 62). According to 
this subtyping for FMD, there will be two types of families with 
MD, with and without migraine, and they reflect the genetic 
heterogeneity in FMD. The families include patients with uni 
and BMD, so epigenetic factors may influence uni or bilateral 
involvement. Most of the described families have an autosomal 
dominant pattern of inheritance, and the participation of several 
genes indicate a genetic heterogeneity in FMD (2, 50). Although 
variable expressivity and incomplete penetrance was observed, 
we did not find cases with episodic ataxia in the families.
Bilateral MD type 4 is associated with migraine in all cases, but 
they do not have familial history of MD. This group may overlap 
with VM, and it may share common pathophysiological mecha-
nisms (63). Patients with MD may show migraine symptoms 
even during the attacks of vertigo (57), and this finding could 
make difficult the differential diagnosis of VM and MD. Magnetic 
resonance imaging may be useful in the diagnostic evaluation of 
patients with the spectrum of VM/MD (MD with concurrent 
migraine or in cases VM and auditory symptoms) (64).
Bilateral MD type 5 could be considered as autoimmune 
MD, since all patients have another concurrent AD. However, 
this group is heterogeneous and includes patients with sporadic 
(71%), FMD (29%), migraine (38%), and both synchronic (38%) 
and metachronic SNHL (62%). Patients with BMD type 5 and 
migraine may have either synchronic or metachronic SNHL.
Our study has several limitations. Despite our efforts to 
improve phenotyping in patients with BMD, we could not 
classify 95 patients with BMD in any cluster, and they were 
excluded of the model. In fact, the largest group (BMD type 1) 
remains poorly characterized, since it is not associated with any 
particular clinical feature or etiological factor. The role of allergy 
in MD deserves more research efforts, since a high prevalence 
of sensitization to inhalant or food allergies have been reported 
in MD (65–67).
However, the recognizing of different subgroups of patients 
and the definition of clinical variants in BMD is not only the first 
step to improve the selection of patients for genetic and immu-
nological studies but also for randomized clinical trials (RCT). 
Most of the RCT performed in MD, were not able to demonstrate 
any effects of diuretics (68) or betahistine (69) and had limited 
TaBle 6 | clinical variants in bilateral Meniere disease (BMD) defined by two-step cluster analysis.
Variables BMD type 1 
(n = 141)
BMD type 2  
(n = 53)
BMD type 3 | 
(n = 39)
BMD type 4  
(n = 36)
BMD type 5  
(n = 34)
p-value
group predictor Metachronic 
snhl
synchronic  
snhl
FMD Migraine aD
Age, mean (SD) 63.3 (11.0) 62.4 (9.5) 54.7 (13.2) 54.1 (11.5) 59.7 (11.1) 0.00001
Gender (% women) 73 (51.8) 30 (56.6) 26 (66.7) 25 (69.4) 24 (70.6) 0.11
Age of onset (SD) 46.4 (13.1) 47.9 (12.0) 40 (14.5) 37 (12.5) 39.8 (11.3) 0.0003
Age of onset ≤40, n (%) 46 (32.6) 15 (28.3) 19 (48.7) 21 (58.3) 16 (47.1) 0.011
Synchronic, n (%) 0 (0.0) 53 (100.0) 7 (17.9) 8 (22.2) 13 (38.2) 3.39 × 10−42
Metachronic, n (%) 141 (100.0) 0 (0.0) 32 (82.1) 28 (77.8) 21 (61.8)
Family history, n (%) 18 (12.8) 7 (13.2) 39 (100.0) 7 (19.4) 19 (55.9) 1.81 × 10−27
FMD, n (%) 0 (0.0) 0 (0.0) 39 (100.0) 0 (0.0) 10 (29.4) 4.10 × 10−53
Headache, n (%) 22 (15.6) 20 (37.7) 14 (35.9) 36 (100.0) 23 (67.6) 4.88 × 10−20
Migraine, n (%) 0 (0.0) 0 (0.0) 7 (17.9) 36 (100.0) 13 (38.2) 1.21 × 10−44
Rheumatoid history, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 34 (100.0) 2.44 × 10−64
Cardiovascular risk factors
High blood pressure, n (%) 46 (34.3) 23 (50.0) 10 (27.0) 11 (34.4) 15 (46.9) 0.15
Dyslipidemia, n (%) 58 (45.3) 26 (53.1) 16 (42.1) 13 (43.3) 15 (45.5) 0.86
Type 2 diabetes, n (%) 23 (17.8) 9 (18.4) 7 (18.4) 1 (3.2) 12 (36.4) 0.019
Smoking, n (%) 31 (22.6) 10 (18.9) 12 (30.8) 6 (17.1) 9 (29.0) 0.53
Significant p values in bold.
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effectiveness for intratympanic gentamicin (70) or steroids (71), 
and these results could be explained by a biased selection of 
patients with different etiologies. Further phenotyping of these 
clinical variants are needed for a better understanding of the 
clinical heterogeneity observed in BMD.
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